In the article by Ratzinger et al entitled “Differential CD52 expression by distinct myeloid dendritic cell subsets: implications for alemtuzumab activity at the level of antigen presentation in allogeneic graft-host interactions in transplantation,” which appeared in the February 15, 2003 issue of Blood (Volume 101:1422-1429), there was an incorrect dosage in the third paragraph under “Cell purification and generation of DCs.” The correct dosage of FLT-3 ligand is 50 ng/mL.
Erratum for vol. 101, p. 1422

Updated information and services can be found at:
http://www.bloodjournal.org/content/105/8/3018.full.html
Articles on similar topics can be found in the following Blood collections

Information about reproducing this article in parts or in its entirety may be found online at:
http://www.bloodjournal.org/site/misc/rights.xhtml#repub_requests

Information about ordering reprints may be found online at:
http://www.bloodjournal.org/site/misc/rights.xhtml#reprints

Information about subscriptions and ASH membership may be found online at:
http://www.bloodjournal.org/site/subscriptions/index.xhtml